• VivoSim announced new preclinical data on its AI-enabled liver and GI toxicity platforms, slated for presentation at ESTIV 2026 on June 29 to July 2.
• Results indicated stronger prediction of liver toxicity than standard animal-based approaches, with fewer incorrect toxicity flags that can sideline viable drug candidates.
• Data also supported use in complex oncology modalities such as antibody-drug conjugates, helping distinguish higher-risk designs from safer profiles earlier in development.
• Management framed the readout as supportive of rising demand as regulators push drugmakers to replace animal testing with human-relevant alternatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290805PRIMZONEFULLFEED9753853) on June 29, 2026, and is solely responsible for the information contained therein.